Suthimon Thumtecho

Suthimon Thumtecho

Auto-generated profile, based on publicly available information

Suthimon Thumtecho

Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Science
Verified
Journal Article
Closed access
KJKristoffer Haurum Johansen
Kristoffer Haurum Johansen
DWDarian Stephan Wolff
Darian Stephan Wolff
BSBeatrice Scapolo
Beatrice Scapolo
MFMonica Fernandez-Quintero
Monica Fernandez-Quintero
CCCharlotte Risager Christensen
Charlotte Risager Christensen
Timothy P. JenkinsTimothy P. Jenkins
Timothy P. Jenkins
The recognition of intracellular antigens by CD8 + T cells through T cell receptors (TCRs) is central for adaptive immunity against infections and cancer. However, the identification of TCRs from patient material remains complex. We present a rapid de novo minibinder (miBd) design platform leveraging state-of-the-art generative models to engineer miBds targeting the cancer-associated peptide-bound major histocompatibility complex (pMHC) SLLMWITQC/HLA-A*02:01 (NY-ESO-1). Incorporating in silico cross-panning enabled computational prescreening of specificity, and molecular dynamics simulations allowed for improved predictability of in vitro success. We identified a high-affinity NY-ESO-1 binder and confirmed its structure using cryo–electron microscopy, which, when incorporated in a chimeric antigen receptor, induced killing of NY-ESO-1 + melanoma cells. We further designed and validated binders to a neoantigen pMHC complex, RVTDESILSY/HLA-A*01:01, with unknown structure, demonstrating the potential for precision immunotherapy.

29 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
SAShirin Ahmadi
Shirin Ahmadi
NBNick J. Burlet
Nick J. Burlet
MBMelisa Benard-Valle
Melisa Benard-Valle
AGAlid Guadarrama-Martínez
Alid Guadarrama-Martínez
SKSamuel Kerwin
Samuel Kerwin
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Each year, snakebite envenoming claims thousands of lives and causes severe injury to victims across sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole treatment option 1 . Traditional antivenoms are expensive, can cause adverse immunological reactions, offer limited efficacy against local tissue damage and are often ineffective against all medically relevant snake species 2 . There is thus an urgent unmet medical need for innovation in snakebite envenoming therapy. However, developing broad-spectrum treatments is highly challenging owing to the vast diversity of venomous snakes and the complex and variable composition of their venoms 3 . Here we addressed this challenge by immunizing an alpaca and a llama with the venoms of 18 different snakes, including mambas, cobras and a rinkhals, constructing phage display libraries, and identifying high-affinity broadly neutralizing nanobodies. We combined eight of these nanobodies into a defined oligoclonal mixture, resulting in an experimental polyvalent recombinant antivenom that was capable of neutralizing seven toxin families or subfamilies. This antivenom effectively prevented venom-induced lethality in vivo across 17 African elapid snake species and markedly reduced venom-induced dermonecrosis for all tested cytotoxic venoms. The recombinant antivenom performed better than a currently used plasma-derived antivenom and therefore shows considerable promise for comprehensive, continent-wide protection against snakebites by all medically relevant African elapids.

1 January 2023 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
STSuthimon Thumtecho
Suthimon Thumtecho
NBNick J. Burlet
Nick J. Burlet
ALAnne Ljungars
Anne Ljungars
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Snakebite envenoming is a significant global health challenge, and for over a century, traditional plasma-derived antivenoms from hyperimmunized animals have been the primary treatment against this infliction. However, these antivenoms have several inherent limitations, including the risk of causing adverse reactions when administered to patients, batch-to-batch variation, and high production costs. To address these issues and improve treatment outcomes, the development of new types of antivenoms is crucial. During this development, key aspects such as improved clinical efficacy, enhanced safety profiles, and greater affordability should be in focus. To achieve these goals, modern biotechnological methods can be applied to the discovery and development of therapeutic agents that can neutralize medically important toxins from multiple snake species. This review highlights some of these agents, including monoclonal antibodies, nanobodies, and selected small molecules, that can achieve broad toxin neutralization, have favorable safety profiles, and can be produced on a large scale with standardized manufacturing processes. Considering the inherent strengths and limitations related to the pharmacokinetics of these different agents, a combination of them might be beneficial in the development of new types of antivenom products with improved therapeutic properties. While the implementation of new therapies requires time, it is foreseeable that the application of biotechnological advancements represents a promising trajectory toward the development of improved therapies for snakebite envenoming. As research and development continue to advance, these new products could emerge as the mainstay treatment in the future.

28 October 2020 in Clinical Toxicology
Verified
Journal Article
Closed access
STSuthimon Thumtecho
Suthimon Thumtecho
CSCharuwan Sriapha
Charuwan Sriapha
ATAchara Tongpoo
Achara Tongpoo
UUUmaporn Udomsubpayakul
Umaporn Udomsubpayakul
WWWinai Wananukul
Winai Wananukul
STSatariya Trakulsrichai
Satariya Trakulsrichai
This study describes the clinical characteristics, outcomes, and factors at presentation associated with death of cases poisoned by glutaraldehyde (GA)-containing products.We performed a 5-year ret...

1 July 2020 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
STSuthimon Thumtecho
Suthimon Thumtecho
TTThunyaporn Tangtrongchitr
Thunyaporn Tangtrongchitr
SSSahaphume Srisuma
Sahaphume Srisuma
TKThanaporn Kaewrueang
Thanaporn Kaewrueang
PRPanee Rittilert
Panee Rittilert
WWWinai Wananukul
Winai Wananukul
Introduction: Green pit vipers (GPV) are widely distributed throughout Thailand and are responsible for significant morbidity. The primary objective of this study was to characterize clinical presentations and treatment methods for GPV bites. The secondary objective was to demonstrate the earliest and latest onset of hematotoxicity. Methods: GPV bites reported to the Ramathibodi Poison Center between July 1, 2016, and June 30, 2018, were analyzed. Results: There were 288 GPV cases within the study period. Patients were predominantly male (62.8%), and the median age was 40 years (interquartile range (IQR) 22.8– 58). Median time from envenomation to hospital presentation was 1 hour (IQR 0.5– 2). Patients were primarily bitten on the finger (27.4%). Most patients reported swelling (90.3%). Necrosis and compartment syndrome occurred in 13 and 9 cases, respectively. Systemic effects occurred in 190 cases (65.9%), with median onset 15 hours (IQR 6– 28.3) post-bite. Venous clotting time (VCT) showed the highest percentage of abnormalities. Systemic bleeding occurred in 13 cases (4.5%). Monitoring patients for 24, 48, and 72 hours after bites detected 62.7%, 85.9%, and 96.5% of cases with systemic effects, respectively. In total, 184 patients (62.5%) were treated, sometimes repeatedly, with antivenoms (285 courses, 949 vials). The most common indication was prolonged VCT (144 courses, 50.5%). Recurrent systemic effects after antivenom occurred in 11 cases (6.1% of patients received antivenom). No recurrence presented as systemic bleeding. Adverse reactions to antivenom were reported in 44 courses (15.4% of 285 courses), being anaphylaxis in 19 courses (6.7%). Other treatments included antibiotics (192 cases, 66.7%), surgical intervention (10, 34.7%), and blood components (4, 1.4%). Conclusion: Most GPV bites result in envenomation. The most frequent local effect is mild swelling. Systemic bleeding is uncommon. The current recommendation of a 3-day follow-up can detect up to 96% of patients who may require antivenom. No severe morbidity or mortality is reported. Antivenoms are primarily indicated by prolonged VCT. Side effects of antivenom are minimal.

1 November 2021 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
TTThunyaporn Tangtrongchitr
Thunyaporn Tangtrongchitr
STSuthimon Thumtecho
Suthimon Thumtecho
JJJiratchaya Janprasert
Jiratchaya Janprasert
KSKitisak Sanprasert
Kitisak Sanprasert
ATAchara Tongpoo
Achara Tongpoo
SSSahaphume Srisuma
Sahaphume Srisuma
Introduction: The Malayan pit viper (MPV; Calloselasma rhodostoma) is a hematotoxic snake found in all regions of Thailand and many countries in Southeast Asia. Treatment of MPV envenomation varies among facilities due to their capabilities. Materials and Methods: This study was a retrospective review of patients with MPV envenomation who were reported to the Ramathibodi Poison Center from 1 July 2016 to 30 June 2018. Results: Of the 167 patients (median age, 40.5 years; range, 1.3– 87.0 years) bitten by an MPV, the most common bite site was the foot (29.3%). Most patients reached the hospital within 1 hour of being bitten. One-hundred fifty-six patients (93.4%) had local effects from envenomation; 17 patients (10.2%) had severe local complications including necrotizing fasciitis (3.0%) and compartment syndrome (7.2%). Systemic effects such as hemorrhage and abnormal hemostasis occurred in 147 patients (88.0%). Additional effects included abnormal venous clotting time in 123 patients (73.7%), unclotted 20-minute whole blood clotting time in 57 patients (34.1%), low platelet counts (< 50,000/μL) in 29 patients (17.4%), prolonged international normalized ratio (> 1.2) in 51 patients (30.5%), and systemic bleeding in 14 patients (8.4%). The median onset of bleeding disorder was 6 hours. Monitoring for 24, 48, and 49 hours after bite enabled detection of systemic effects in 94.2%, 99.3%, and 100.0%, respectively. Three hundred fifteen courses of antivenin were administered to 144 patients (86.2%). All the patients who received antivenin recovered from bleeding disorder. Only 7.0% of antivenin doses were administered without Thai Red Cross indications. Allergic reactions from antivenin occurred in 34.7% of the 144 patients. One hundred thirty patients (77.8%) received antibiotics, and 32 patients (19.2%) required surgical management, including debridement and fasciotomy. Conclusion: MPV envenomation results in local and systemic effects. Most systemic effects were abnormal clotting test results. Most patients reported onset of bleeding disorder within 48 hours.